China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
CAMBRIDGE, Mass., April 20, 2017 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 5th Annual Cell & Gene Therapy Investor Day in Boston, MA on Thursday, April 27, 2017 at 2:30pm Eastern Time.
The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: http://investors.vcel.com/events.cfm.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
